ABCG2 and lymphoma: Despite the fact that PSC833 failed to improve the outcome in humans with recurrent or DR multiple myeloma [159], it has to be realized that both veterinary studies describe the use of PSC833 in dogs with non-DR tumors, and it is therefore too early to conclude that PSC833 has no use in the treatment of dogs with (ABC-transporter mediated) DR lymphoma.